HBB FSC 36-37 (-T) Gene Mutation Detection in Carriers of Thalassemia Minor Using High Resolution Melting Analysis

Document Type : Research Article


1 Department of Genetics, Faculty of Basic Sciences, Shahrekord University, Shahrekord, Iran

2 Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Child Growth and Development Research Center, Research Institute for Primordial Prevention of NonCommunicable Disease

4 Research Institute of Biotechnology, Shahrekord University, Shahrekord, Iran


Beta-thalassemia is one of the most common autosomal recessive disorders in the world population resulting from over 200 different mutations of HBB gene. Beta-thalassemias are caused by point mutations or, more rarely, deletions in the HBB gene leading to reduced (beta+) or absent (beta0) synthesis of the beta chains of hemoglobin (Hb). High-resolution melting of polymerase chain reaction (PCR) products can detect heterozygous and most homozygous mutations without electrophoretic or chromatographic separations.
In the current study, blood samples collected from 20 individuals carrying minor thalassemia were genotyped using HRM technique. The genotype of each sample had been previously determined via the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)/ amplification-refractory mutation system (ARMS) or sequencing method. This study aimed to determine the specificity and sensitivity of HRM method in the diagnosis of carriers of FSC 36-37 (-T) mutation from carriers who do not have this mutation. DNA extraction from peripheral blood was performed and HRM method was used to genotype samples. The results were analyzed according to the normalized and difference plot. High-resolution melting analysis could correctly identify all carriers of FSC 36-37 (-T) from who did not have this mutation. In summary, HRM is a technique associated with high sensitivity and specificity. Therefore, HRM is an appealing technique for the identification of FSC 36-37 (-T) mutation.


Akhavan-Niaki H, Derakhshandeh-Peykar P, Banihashemi A, Mostafazadeh A, Asghari B, Ahmadifard MR, Azizi M, Youssefi A, Elmi MM. 2011. A comprehensive molecular characterization of beta thalassemia in a highly heterogeneous population. Blood Cells Mol Dis 47(1): 29-32.
Akhondi F, Emadi-Baygi M, Salehi M, Nikpour. P. 2016. Detection of IVSII-1 mutation of beta globin gene in carriers of thalassemia minor using high-resolution melting analysis [In Persian]. J Isfahan Med Sch 33(363): 2179-2186.
Amir M, Emadi Baygi M, Vallian S, Nikpour P and Akhoundi F. 2017. Molecular assessment and bioinformatic analysis of two common mutations of phenylalanine hydroxylase (PAH) gene by HRM [In Persian]. J Babol Univ Med Sci 19(6): 42-49.
Baig S, Azhar A, Hassan H, Baig J, Kiyani A, Hameed U, Rabbi F, Bokhari H, Aslam M, Din MU. 2006. Spectrum of beta-thalassemia mutations in various regions of Punjab and Islamabad, Pakistan: establishment of prenatal diagnosis. Haematologica 91(3): ELT02-ELT02.
Baig SM. 2007. Molecular diagnosis of β‐thalassemia by multiplex ARMS‐PCR: a cost effective method for developing countries like Pakistan. Prenat Diag 27(6): 580-581.
Birgens H, Ljung R. 2007. The thalassaemia syndromes. Scand J Clin Lab Invest 67(1): 11-26.
Bunn HF, Forget BG. 1986. Hemoglobin--molecular, genetic, and clinical aspects, WB Saunders Co.
Chang PL, IT Kuo, Chiu TC, Chang HT. 2004. Fast and sensitive diagnosis of thalassemia by capillary electrophoresis. Anal Bioanal Chem 379(3): 404-410.
Chern SR, Chen CP. 2000. Molecular prenatal diagnosis of thalassemia in Taiwan. Int J Gynecol Obstet 69(2): 103-106.
Das S, Talukder G. 2001. A review on the origin and spread of deleterious mutants of the β-globin gene in Indian populations. HOMO 52(2): 93-109.
Doosti iA, Cheraghi Z, Bitaraf S, Cheraghi P, Safiri S. 2015. Prevalence of Alpha and Beta-Thalassemia Mutations among Carriers of Thalassemia in Shadegan City, Southwest of Iran. Zahedan J Res Med Sci 17(8): e1032.
Dozy AM, Kan YW. 1994. Characterization of β‐thalassemia mutations by denaturing gradient gel electrophoresis: patterns in the Mediterranean mutations. Clin Genet 45(5): 221-227.
Grosso M, Sessa R, Puzone S, Storino MR, Izzo P. 2012. Molecular basis of Thalassemia. In: Anemia Causes. Dipartimento di Biochimica e Biotecnologie Mediche, University of Naples, Federico II, Italy, p. 341-360 (February 2012).
Grosveld F, Boer E, Dillon N, Gribnau J, Milot E, Trimborn T, Wijgerde M, Frasera P. 1998. The dynamics of globin gene expression and gene therapy vectors. Ann NY Acad Sci 850(1): 18-27.
Habibzadeh F, Yadollahie M, Merat A, Haghshenas M. 1998. Thalassemia in Iran; an overview. Arch Iran Med 1(1): 27-33.
Hashemizadeh H, Noori R. 2013. Premarital screening of beta thalassemia minor in north-east of Iran. Iran J Ped Hematol Onco 3(1): 210.
Lahiry P, Al-Attar S, Hegele R. 2008. Understanding beta-thalassemia with focus on the Indian subcontinent and the Middle East. Open Hematol J 2: 5-13.
Liew M, Pryor R, Palais R, Meadows C, Erali M, Lyon E, Wittwer C. 2004. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem 50(7): 1156-1164.
Marashi SJ, Eshkoor SA, Mirinargesi M saed, Sarookhan MRi, Rahmat AB, Ismail PB. 2012. Detection of eight common beta globin gene mutation in thalassemia major patients using real time polymerase chain reaction (PCR)-high resolution melting and EvaGreen (TM) dye. Afr J Biotechnol 11(2): 448.
McKinney J, Longo N, Hahn S, Matern D, Rinaldo P, Strauss A, Dobrowolski S. 2004. Rapid, comprehensive screening of the human medium chain acyl-CoA dehydrogenase gene. Mol Genet Metab 82(2): 112-120.
Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian S, Sahebjam F, Amirizadeh N, Karimi-Nejad MH. 2001. The β-thalassemia mutation spectrum in the Iranian population. Hemoglobin 25(3): 285-296.
Najmabadi H, Pourfathollah AA, Neishabury M, Sahebjam F, Krugluger W, Oberkanins C. 2002. Rare and unexpected mutations among Iranian beta-thalassemia patients and prenatal samples discovered by reverse-hybridization and DNA sequencing. Haematologica 87(10): 1113-1114.
Prathomtanapong P, Pornprasert S, Phusua A, Suanta S, Saetung R and Sanguansermsri T. 2009. Detection and identification of β‐thalassemia 3.5 kb deletion by SYBR Green and high resolution melting analysis. Eur Journal Haematol 82(2): 159-160.
Rahimi Z. 2013. Genetic epidemiology, hematological and clinical features of hemoglobinopathies in Iran. Biomed Res Int 2013.
Reichert VC, De Castro SM, Wagner SC, Dulcinéia M, Hutz MH, Leistner-Segal S. 2008. Identification of β thalassemia mutations in South Brazilians. Ann Hematol 87(5): 381-384.
Rosatelli MC, Tuveri T, Scalas MT, Leoni GB, Sardu R, Faa V, Meloni A, Pischedda MA, Demurtas M, Monni G. 1992. Molecular screening and fetal diagnosis of β-thalassemia in the Italian population. Hum Genet 89(6): 585-589.
Shih HC, Er TK, Chang TJ, Chang YS, Liu TC, Chang JG. 2009. Rapid identification of HBB gene mutations by high-resolution melting analysis. Clin Biochem 42(16): 1667-1676.
Urbinati F, Madigan C, Malik P. 2006. Pathophysiology and therapy for haemoglobinopathies; Part II: thalassaemias. Expert Rev Mol Med 8(10): 1-26.
Vrettou C, Traeger-Synodinos J, Tzetis M, Malamis G, Kanavakis E. 2003. Rapid screening of multiple β-globin gene mutations by real-time PCR on the LightCycler: application to carrier screening and prenatal diagnosis of thalassemia syndromes. Clin Chem 49(5): 769-776.
Ward MA, Olivieri NF, Ng J, Roder JC. 1991. Detection of beta-thalassemia using an artificial-restriction fragment length polymorphism generated by the polymerase chain reaction. Nucleic Acids Res 19(4): 959.
Weatherall D, Clegg JB. 2001. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 79: 704-712.
Willmore C, Holden JA, Zhou L, Tripp S, Wittwer CT, Layfield LJ. 2004. Detection of c-kit–activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis. Am J Clin Path 122(2): 206-216.
Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. 2003. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49(6): 853-860.
Zhou L, Myers AN, Vandersteen JG, Wang L, Wittwer CT. 2004. Closed-tube genotyping with unlabeled oligonucleotide probes and a saturating DNA dye. Clin Chem 50(8): 1328-1335.
Zhou L, Vandersteen J, Wang L, Fuller T, Taylor M, Palais B, Wittwer C. 2004. High‐resolution DNA melting curve analysis to establish HLA genotypic identity. Tissue Antigens 64(2): 156-164.